Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
20 October 2020 - 11:30PM
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology
company developing next-generation vaccines for serious infectious
diseases, today announced that Gregory M. Glenn, M.D, President of
Research & Development, will present on NVX-CoV2373, the
Company’s COVID-19 vaccine, at the 2020 World Vaccine Congress
Europe. The Congress takes place virtually October 19 - 21, 2020.
Presentation Title: |
Recombinant nanoparticle COVID-19
vaccine: Platform technology for Emerging Infectious Diseases
(EID) |
Time: |
14:10 CET/8:10 am ET |
For more information on the Congress or to
register, please click here.
About NVX-CoV2373NVX-CoV2373 is a vaccine
candidate engineered from the genetic sequence of SARS-CoV-2, the
virus that causes COVID-19 disease. NVX-CoV2373 was created using
Novavax’ recombinant nanoparticle technology to generate antigen
derived from the coronavirus spike (S) protein and contains
Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the
immune response and stimulate high levels of neutralizing
antibodies. NVX-CoV2373 contains purified protein antigen and
cannot replicate, nor can it cause COVID-19. In preclinical trials,
NVX-CoV2373 demonstrated induction of antibodies that block binding
of spike protein to receptors targeted by the virus, a critical
aspect for effective vaccine protection. In the Phase 1 portion of
its Phase 1/2 clinical trial, NVX-CoV2373 was generally
well-tolerated and elicited robust antibody responses numerically
superior to that seen in human convalescent sera. NVX-CoV2373 is
also being evaluated in a Phase 3 trial in the UK and two ongoing
Phase 2 studies that began in August; a Phase 2b trial in South
Africa, and a Phase 1/2 continuation in the U.S. and Australia.
Novavax has secured $2 billion in funding for its global
coronavirus vaccine program, including up to $388 million in
funding from the Coalition for Epidemic Preparedness Innovations
(CEPI).
About NovavaxNovavax,
Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that
promotes improved health globally through the discovery,
development, and commercialization of innovative vaccines to
prevent serious infectious diseases. Novavax is undertaking
clinical trials for NVX-CoV2373, its vaccine candidate against
SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its
quadrivalent influenza nanoparticle vaccine, met all primary
objectives in its pivotal Phase 3 clinical trial in older adults.
Both vaccine candidates incorporate Novavax’ proprietary
saponin-based Matrix-M™ adjuvant to enhance the immune response and
stimulate high levels of neutralizing antibodies. Novavax is a
leading innovator of recombinant vaccines; its proprietary
recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce highly immunogenic
nanoparticles in order to address urgent global health needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts:InvestorsErika
Trahanir@novavax.com240-268-2022
MediaBrandzone/KOGS CommunicationEdna
Kaplankaplan@kogspr.com617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From May 2023 to May 2024